Anti-inflammatory Effect of Resveratrol and Polydatin by In Vitro IL-17 Modulation
- 754 Downloads
Interleukin-17 (IL-17) is a proinflammatory cytokine produced, although not exclusively, by T helper 17 recently identified as a distinct T helper lineage mediating tissue inflammation. IL-17 is known to be involved in a number of chronic disorders although the mechanisms regulating its production in inflammatory disease are still unclear. The beneficial properties of the polyphenolic compound resveratrol including its anti-inflammatory, antioxidant, and antitumor effects, its role in the aging process and in the prevention of heart and neurodegenerative diseases are well-known. In addition, derivatives of resveratrol, including glucosylated molecules as polydatin have been linked to similar beneficial effects. We have investigated the effects of resveratrol and polydatin on the in vitro production of IL-17 in a model of inflammation in vitro. The results obtained by activated human peripheral blood mononuclear cells, stimulated with anti-CD3/anti-CD28 monoclonal antibodies and treated with these polyphenolic compounds at different concentrations show that both decrease IL-17 production in a concentration-dependent manner. This study confirms the anti-inflammatory activity of resveratrol and its derivatives and suggests a potential clinical relevance in the therapy of inflammatory diseases.
KEY WORDSresveratrol polydatin interleukin 17 inflammation
This work was partially supported by Ministero dell’Istruzione, dell’Università e della Ricerca Rome, Italy.
We are grateful to Fulvio Mattivi for generously providing purified resveratrol and polydatin.
- 24.Petro TM. 2010. Regulatory role of resveratrol on Th17 in autoimmune disease. Int Immunopharmacol. Aug 12.Google Scholar
- 25.Mikulski, D., and M. Molski. 2010. Quantitative structure-antioxidant activity relationship of trans-resveratrol oligomers, trans-4, 4′-dihydroxystilbene dimer, trans-resveratrol-3-O-glucuronide, glucosides: trans-piceid, cis-piceid, trans-astringin and trans-resveratrol-4′-O-beta-d-glucopyranoside. European Journal of Medicinal Chemistry 45(6): 2366–2380.PubMedCrossRefGoogle Scholar
- 27.Rovedatti, L., T. Kudo, P. Biancheri, M. Sarra, C.H. Knowles, D.S. Rampton, G.R. Corazza, G. Monteleone, A. Di Sabatino, and T.T. Macdonald. 2009. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 58(12): 1629–1636.PubMedCrossRefGoogle Scholar
- 28.Shen H, Xia L, Lu J, Xiao W. 2011. Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand J Rheumatol. Jan 13.Google Scholar
- 30.G. Ravagnan, R. Falchetti, G. Lanzilli, M.P. Fuggetta, M. Tricarico and F. Mattivi. Solid phase extraction of trans-resveratrol from wines for HPLC analysis. Use of extracts from spermatophyte plants with immunomodulating activity, Pat. EP 1 292 320)Google Scholar
- 33.Fuggetta, M.P., G. Lanzilli, M. Tricarico, A. Cottarelli, R. Falchetti, G. Ravagnan, and E. Bonmassar. 2006. Effect of resveratrol on proliferation and telomerase activity of human colon cancer cells in vitro. Journal of Experimental & Clinical Cancer Research 25(2): 189.Google Scholar
- 43.Chen, Z., A. Laurence, Y. Kanno, M. Pacher-Zavisin, B.M. Zhu, C. Tato, A. Yoshimura, L. Hennighausen, and J.J. Shea. 2006. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proceedings of the National Academy of Sciences of the United States of America 103(21): 8137–8142.PubMedCrossRefGoogle Scholar